Target intelligence / Profile preview

Prostate tumor-associated antigens

Molecular classification: Other (heterogeneous group of antigens rather than one molecule), Receptor (subset; some targets are membrane receptors such as CEACAM5 in neuroendocrine prostate cancer), Enzyme (subset; e.g., PAP/ACPP is an acid phosphatase enzyme; PSMA/FOLH1 is a glutamate carboxypeptidase), Transporter/Cell-surface protein (subset; PSMA/FOLH1 is a transmembrane cell-surface enzyme often targeted as a “receptor-like” antigen), Antigen/Tumor-associated antigen (immunologic classification), Cancer-testis antigen (subset; e.g., NY-ESO-1, MAGE family)

Overview

Prostate tumor-associated antigens are a heterogeneous set of proteins expressed by prostate tumors (and often by normal or lineage-related prostate cells) that can be recognized by the immune system and exploited as therapeutic targets or biomarkers; they include prostate lineage antigens (e.g., PSA/KLK3, PSMA/FOLH1, PAP/ACPP), cancer-testis antigens (e.g., NY-ESO-1 and MAGE family), and subtype-specific surface proteins (e.g., CEACAM5 in neuroendocrine prostate cancer). These antigens are used for immunotherapies such as vaccines and CAR-T approaches and for diagnostic/prognostic stratification, but their expression is variable across molecular subtypes and disease states, necessitating careful biomarker-driven patient selection.

Other names: Prostate cancer–associated antigensProstate tumor antigensProstate-associated tumor antigensProstate cancer antigens

Mechanism of action

Cancer vaccine–induced T-cell responses against prostate tumor-associated antigens (e.g., PAP with sipuleucel-T; CTAs like NY-ESO-1/MAGE) Chimeric antigen receptor T cells mediating antigen-specific cytotoxicity against surface antigens (e.g., CEACAM5 in NEPC, preclinical proof-of-concept) Antibody- or ligand-directed targeting of cell-surface antigens for cytotoxic delivery or immune engagement (general for prostate TAAs; specific examples vary by antigen)

Biological functions

Immune recognition as tumor-associated antigens (antigenicity for T-cell or antibody targeting)Signal transduction and cell adhesion (subset; e.g., CEACAM5-mediated adhesion/singaling in cancers)Enzymatic activity in prostate tissue biology and tumor biology (subset; e.g., PSMA/FOLH1, PAP/ACPP)Androgen signaling lineage programs drive expression of several prostate lineage antigens used as targets/biomarkers

Disease associations

Cancer (Prostate cancer; includes adenocarcinoma and neuroendocrine prostate cancer subtypes)Other (biomarker roles in prognosis and patient stratification across molecular classes)

Safety considerations

Antigen heterogeneity and variable expression across prostate cancer subtypes (risk of inadequate coverage or antigen-loss escape)On-target/off-tumor toxicity for antigens with extra-prostatic expression (e.g., CEACAM5 in other epithelial tissues)Immune-related adverse events from vaccine/CAR-T approaches; risk depends on antigen specificity and tissue distributionEvolution to neuroendocrine lineage with altered antigen surfaceome, causing loss of adenocarcinoma targets and necessitating different antigens (e.g., CEACAM5 for NEPC)Patient selection challenges due to molecular heterogeneity and AR pathway dynamics affecting antigen expression

Interacting drugs

Sipuleucel-T (autologous cellular immunotherapy targeting prostatic acid phosphatase, a prostate tumor-associated antigen)

2 more in the full profile.

Biomarkers

Prostate-specific antigen (PSA/KLK3) as a prostate lineage biomarker; widely used clinically for monitoring (commonly considered a prostate-associated antigen)Prostate-specific membrane antigen (PSMA/FOLH1) expression as an imaging and therapeutic selection biomarker in prostate adenocarcinomaCancer-testis antigens (e.g., NY-ESO-1, MAGE family) expression as biomarkers for immunotherapy eligibility in subsets of prostate cancer, especially advanced/CRPCCEACAM5 expression as a biomarker of neuroendocrine prostate cancer phenotype and potential immunotherapy targeting in NEPCMolecular subtypes and AR activity states that co-stratify antigen expression and therapy responsiveness (e.g., TCGA subtypes, PCS/PAM50) guiding selection and prognosis

Beyond the preview

Go deeper on Prostate tumor-associated antigens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostate tumor-associated antigens.

Explore the full profile